Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
March 28, 2024 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
August 16, 2023 10:56 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Ad Scientiam Logo
Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
February 28, 2023 08:00 ET | Ad Scientiam
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel...
Ad Scientiam Logo
Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
February 28, 2023 08:00 ET | Ad Scientiam
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
November 09, 2022 16:11 ET | Catalyst Pharmaceuticals, Inc.
Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
November 07, 2022 08:03 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...